The Coca-Cola Co K vs Moderna, Inc. — how do they compare? The Coca-Cola Co K trades at $86.32 (market cap $372.08B), while Moderna, Inc. trades at $60.53 (market cap $24.18B). The key difference: The Coca-Cola Co K is far larger — about 15.4× Moderna, Inc.'s market cap, and The Coca-Cola Co K pays a 2.45% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| KO | MRNA | |
|---|---|---|
Market Cap | $372.08B | $24.18B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $89.08 | $81.80 |
52-Week Low | $65.67 | $22.36 |
Enterprise Value | $399.26B | $20.33B |
Dividend Yield | 2.45% | — |
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding the $0.92 forecast. Key valuation ratios include a P/E of 26.09 and ROE of 44.23%, while cash flow trends show robust operational performance. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook remains positive with a consensus price target of $95.83, implying 10.3% upside. Strengths include a 64-year dividend growth streak and high profitability, but risks involve regional demand divergence and elevated debt levels. Analyst sentiment is bullish with 60% buy ratings, supporting a favorable investment case for long-term holders.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →